- Home
- MNPR vs TEAD Comparison
MNPR vs TEAD Comparison
Compare MNPR & TEAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- TEAD
- Stock Information
- Founded
- MNPR 2014
- TEAD 2006
- Country
- MNPR United States
- TEAD United States
- Employees
- MNPR N/A
- TEAD N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- TEAD
- Sector
- MNPR Health Care
- TEAD
- Exchange
- MNPR Nasdaq
- TEAD NYSE
- Market Cap
- MNPR 209.3M
- TEAD 241.4M
- IPO Year
- MNPR 2019
- TEAD N/A
- Fundamental
- Price
- MNPR $44.97
- TEAD $2.95
- Analyst Decision
- MNPR Strong Buy
- TEAD
- Analyst Count
- MNPR 7
- TEAD 0
- Target Price
- MNPR $62.00
- TEAD N/A
- AVG Volume (30 Days)
- MNPR 69.5K
- TEAD 396.1K
- Earning Date
- MNPR 08-08-2025
- TEAD 08-16-2025
- Dividend Yield
- MNPR N/A
- TEAD N/A
- EPS Growth
- MNPR N/A
- TEAD N/A
- EPS
- MNPR N/A
- TEAD N/A
- Revenue
- MNPR N/A
- TEAD $959,268,000.00
- Revenue This Year
- MNPR N/A
- TEAD $65.64
- Revenue Next Year
- MNPR N/A
- TEAD $5.29
- P/E Ratio
- MNPR N/A
- TEAD N/A
- Revenue Growth
- MNPR N/A
- TEAD 4.15
- 52 Week Low
- MNPR $1.72
- TEAD $2.32
- 52 Week High
- MNPR $54.30
- TEAD $7.87
- Technical
- Relative Strength Index (RSI)
- MNPR 59.21
- TEAD N/A
- Support Level
- MNPR $44.26
- TEAD N/A
- Resistance Level
- MNPR $47.52
- TEAD N/A
- Average True Range (ATR)
- MNPR 3.49
- TEAD 0.00
- MACD
- MNPR 0.54
- TEAD 0.00
- Stochastic Oscillator
- MNPR 64.49
- TEAD 0.00
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About TEAD TEADS HLDG CO
Teads Holding Co is the omnichannel outcomes platform for the open internet, driving full-funnel results for marketers across premium media. Its Focus on meaningful business outcomes for branding and performance objectives, the combined company ensures value is driven with every media dollar by leveraging predictive AI technology to connect quality media, beautiful brand creative, and context-driven addressability and measurement.